Joseph Wagner joined Notable as chief scientific officer in 2020. With nearly 20 years of experience in biotechnology, he leads the scientific platform at Notable, focusing on developing innovative therapeutics.
Before joining Notable, Wagner was the executive director of the University of California Drug Discovery Consortium (UC-DDC). He has also held CEO and CTO roles at BriaCell Therapeutics, OncoCyte and Cell Targeting, where he guided the development of small molecule and biologic therapeutics from bench studies to Phase II clinical trials.
Wagner’s expertise spans multiple therapeutic areas, including oncology, neurology and cardiovascular disease. He has also led bioinformatic efforts to identify novel targets, biomarkers and companion diagnostics.
Wagner earned a bachelor of science degree in neuroscience from the University of Rochester in Rochester, N.Y. and a Ph.D. in pharmacology from Duke University in Durham, N.C.
